HDL and ApoA-I are prone to post-translational modifications, which can directly lead to HDL dysfunction. 6 We have previously shown that ApoA-I is a preferred and selective target for myeloperoxidase-mediated modification, which leads in vitro to a loss of its ability to promote cholesterol efflux from macrophages-a crucial step in RCT. 20 Furthermore, increased levels of myeloperoxidase-modified ApoA-I have been found in the circulation of patients with coronary artery disease and in human atherosclerotic plaques. [21] [22] [23] [24] We therefore hypothesized that myeloperoxidase-mediated oxidation of ApoA-I would impair its function to promote RCT in vivo and to mediate beneficial effects on atherosclerotic plaques. Here, we test these hypotheses in mouse models after injections of native and myeloperoxidase-treated ApoA-I.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Levels and Distribution of Human Native and Oxidized ApoA-I in the Plasma After Subcutaneous Injection
First, we determined the levels of human native and oxidized ApoA-I in the plasma of apolipoprotein E-deficient (ApoE −/− ) mice at 8 and 24 hours after subcutaneous injection of both forms (15 mg each). At 8 hours after the injection, there were comparable plasma levels of native and oxidized ApoA-I, with the latter declining by 24 hours ( Figure I in the online-only Data Supplement).
Next, we sought to evaluate the distribution of native and oxidized ApoA-I in the plasma of mice 8 hours after the injection by fast performance liquid chromatography, with subsequent Western blot analyses of the individual fast performance liquid chromatography fractions using anti-total human ApoA-I monoclonal antibody 10G1.5 24 ( Figure 1A-1D ). After the injection of native ApoA-I, we found the expected immunoreactive band migrating at ≈27 kDa, corresponding to the ApoA-I monomer protein ( Figure 1C ). After the injection of oxidized ApoA-I, high amounts of slower migrating immunoreactive ApoA-I-containing protein bands with molecular weights around ≈50, ≈75, and ≈100 kDa appeared in addition to the ApoA-I monomer band at ≈27 kDa ( Figure 1D ). These bands represent oxidatively cross-linked dimeric and multimeric forms of ApoA-I, as we have previously reported from human aortas. 24 For technical reasons, the large amount of cross-linked protein in oxidized ApoA-I renders it confusing to examine its distribution by fast performance liquid chromatography because it is simultaneously associated with a wide range of molecular weights. Thus, we evaluated the plasma distribution of native and oxidized ApoA-I by Western blot analysis after buoyant density gradient centrifugation ( Figure 1E-1G) . In contrast to native ApoA-I, which was almost completely recovered within the HDL fraction, only ≈35% of oxidized ApoA-I was associated with HDL particles, whereas ≈65% resided within the lipoprotein-deficient fraction ( Figure 1E and 1G) . Although there was almost no crosslinked ApoA-I detectable after the injection of native ApoA-I in the HDL or lipoprotein-deficient fraction, high levels of cross-linked ApoA-I were present in both fractions after the injection of the oxidized form ( Figure 1F and 1G) .
Impact of Oxidation of ApoA-I on Plasma HDL-C Levels and RCT
In vitro studies have shown that myeloperoxidase-oxidized ApoA-I loses the ability to facilitate cholesterol efflux from cells via the ATP-binding cassette transporter A1-dependent pathway. 20 To test the hypothesis whether myeloperoxidasemediated oxidation of human ApoA-I impairs its RCT activity in vivo, we quantified plasma HDL-C levels and RCT (to plasma, liver and, feces) in ApoA-I −/− mice injected subcutaneously at time 0 and 24 hours with 0.4 mg/g of body weight of native ApoA-I, oxidized ApoA-I, or the saline carrier (control). We observed that plasma HDL-C levels were significantly increased in mice injected with native ApoA-I compared with the control group at 24, 48, and 72 hours (2.1-, 3.2-, and 2.5-fold, respectively; P<0.001; Figure 2A ). Meanwhile, plasma HDL-C levels were significantly lower in mice injected with oxidized ApoA-I compared with the control group at 24 and 72 hours (by ≈40% and ≈41.5%, respectively; P<0.01).
RCT was measured by determining the [ 3 H]cholesterol transported from subcutaneously injected foam cells to plasma, liver, and feces for 3 days. RCT to the plasma was significantly increased in mice injected with native ApoA-I at all 3 time points by 3.4-, 4.7-, and 3.6-fold, respectively (P<0.01 for 24 hours plasma RCT and P<0.001 for 48 and 72 hours; Figure 2B ). RCT to the plasma was lower in mice injected with oxidized ApoA-I compared with the control group, reaching statistical significance at the 72-hour time point (64% lower; P<0.01). RCT to the liver was significantly higher in mice injected with native ApoA-I when compared with the control group (39% increase; P<0.01; Figure 2C ). Meanwhile, RCT to the liver was 26% lower in mice injected with oxidized ApoA-I compared with the control group. The same pattern was observed for fecal RCT, and although statistically not significant, fecal RCT was increased by 84% in mice injected with native ApoA-I compared with the control group, whereas it remained almost unchanged in mice injected with oxidized ApoA-I (−2% compared with the control group; Figure 2D ). Thus, native ApoA-I increased plasma HDL-C and RCT, whereas oxidized ApoA-I failed to raise HDL-C or promote RCT.
To determine whether, in addition to its impaired intrinsic efflux activity, oxidized ApoA-I inhibits the cholesterol efflux activity of native ApoA-I, we performed a mixing experiment in vitro. As previously shown, 20 oxidized ApoA-I has limited cholesterol efflux activity; however, adding an equal concentration to native ApoA-I did not inhibit the cholesterol efflux activity of the native protein ( Figure II in the online-only Data Supplement). Preclinical and clinical studies have shown that raising ApoA-I by infusion or overexpression leads to beneficial changes in the plaque composition, including fewer macrophages, reduced lipid content, and more collagen. 6 To test the hypothesis whether myeloperoxidase-mediated oxidation of human ApoA-I impairs these effects of ApoA-I, hyperlipidemic ApoE −/− mice were injected subcutaneously with 15 mg (per injection) of human native ApoA-I, oxidized ApoA-I, or the carrier (control) 4 times (every other day); the baseline plasma total cholesterol levels of the 3 injection groups were 1220±66, 1059±50, and 1044±86 mg/dL, respectively, which did not differ significantly from each other (P=0.2). The injections were well tolerated by all mice. Enrichment of either native or oxidized human ApoA-I was detectable in aortic root plaques of the injected mice ( Figure III in the online-only Data Supplement), indicating that both forms of ApoA-I were able to leave the circulation and gain access to the intimal areas.
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We did not observe a significant difference (P=0.9) in the absolute plaque size between the 3 groups within this short-term treatment period ( Figure 3A ). There was, however, a significant decrease in plaque (CD68 plaques only in the native ApoA-I-treated group (32.2±1.6% of plaque area) compared with the control group (46.1±1.3% of plaque area; P<0.001; Figure 3B and 3C). Similarly, lipid content (ie, Oil Red O staining) was found to be significantly decreased in the native ApoA-I group (28.6±1.5% of plaque area) compared with the control group (36.8±0.7% of plaque area; P<0.001) and the oxidized ApoA-I group (34.2±0.6% of plaque area; P<0.001; Figure 3D ). In contrast, there were no significant differences in the plaque macrophage and lipid contents between the oxidized ApoA-I and the control group.
Next, we evaluated the effect of native and oxidized ApoA-I on plaque collagen content, a marker associated with increased stability in human plaques. Only the native ApoA-I-treated group had significantly increased plaque collagen content (11.2±1.3%) compared with the oxidized ApoA-I (6.6±0.5%; P<0.01) and control (6.6±0.7%; P<0.01) groups, whereas the latter 2 groups did not differ significantly ( Figure 3E ). This may have reflected the combined trends in the gene expression of a stimulator of collagen synthesis, transforming growth factor-β, in laser-captured CD68 + macrophages ( Figure 
Attenuated Induction of CCR7 and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Expression in Plaque Macrophages by Oxidized ApoA-I
We have previously demonstrated in multiple mouse models that during the regression phase, CD68 + cells emigrate from the plaques in a process in which the chemokine receptor CCR7 is upregulated. 9, 25 Notably, CCR7 mRNA expression was significantly increased in laser-captured CD68 + plaque cells of mice injected with native ApoA-I (4.7±1.4-fold; P<0.05), but not oxidized ApoA-I (2.3±0.6-fold), compared with the control group ( Figure 4A) . The changes at the CCR7 mRNA levels were consistent with those observed at the protein level ( Figure 4B ). The human and mouse CCR7 promoter contain sterol response elements, and hence, the cellular sterol content is an important regulator of CCR7 gene expression. 26 The reduction in plaque cholesteryl ester content (as judged by Oil Red O staining) in the plaques of native ApoA-I-injected mice and the significant increase in the expression of the sterol-regulated gene, 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG CoA) in laser-captured CD68 + plaque cells from these mice (2.7±0.6-fold compared with the control group; P<0.05) support this finding. There was a more modest and nonsignificant increase in HMG-CoA reductase 
Effect of Oxidized ApoA-I on the Inflammatory State of Plaque Macrophages
In addition to the changes in plaque macrophage content, we evaluated their inflammatory state. The mRNA expression of the proinflammatory M1 macrophage marker interleukin-1β (IL-1β) in laser-captured plaque CD68 + cells was significantly reduced after the injection of native ApoA-I (to 0.5±0.1; P<0.05). In marked contrast, no reduction was noted in IL-1β in plaque-derived CD68 + cells after the injection of oxidized ApoA-I compared with the control group ( Figure 5A ). Consistent with this was the finding that the mRNA expression of monocyte chemoattractant protein-I (MCP-I), an M1 macrophage marker and a target of nuclear factor-κB that is involved in the recruitment of monocytes into atherosclerotic plaques, was significantly reduced only in laser-captured CD68 + plaque cells in the native ApoA-I group (to 0.4±0.1; P<0.01) compared with the control group ( Figure 5B ). The changes in the MCP-I mRNA level were consistent with those at the protein level ( Figure 5C ). In contrast, there was a significant increase in anti-inflammatory M2 macrophage markers mannose receptor 1 and arginase-I protein in the plaques of the native ApoA-I-injected group (26.6±1.9% of plaque area, P<0.01 and 23.6±3.6% of plaque area, respectively) compared with the control group (17.1±1.9% of plaque area, P<0.01 and 12.4±2.6% of plaque area, P<0.05, respectively) and the oxidized ApoA-I group (18.4±0.6% of plaque area, P<0.01 and 12.3±2.0% of plaque area, P<0.05, respectively). Again, in marked contrast to the results for native ApoA-I, the results in the oxidized ApoA-I and control groups did not differ significantly ( Figure 5D and 5E).
Discussion
Epidemiological studies have clearly shown an inverse relationship between levels of HDL-C and cardiovascular risk. 1 HDL particles play a central role in RCT and exhibit antioxidant, anti-inflammatory, antithrombotic activities and improve endothelial function. 6 Preclinical studies and small clinical studies have shown that raising HDL-C by providing functional particles or ApoA-I can halt the progression, and even induce the regression, of atherosclerosis.
3,5,7-9,11,13,15 However, recent reports from the large clinical outcome studies aimed at raising HDL-C levels with either cholesteryl ester transfer protein inhibitors or niacin (as add-on therapy to statins) have thus far failed to demonstrate clinical benefit. 17, 18, 27 Similarly, results from a recent Mendelian randomization study failed to show an association between genetic variants controlling HDL-C levels and cardiovascular disease risks, raising doubts about HDL-C targeted therapeutic strategies for the treatment or prevention of cardiovascular disease. 17, 19, [27] [28] [29] [30] Importantly, most of these clinical intervention or Mendelian genetics studies have thus far focused on HDL-C levels, and not ApoA-I. Furthermore, neither were the functional properties of the HDL particles examined with the above pharmacological interventions (or genetic studies) nor was the HDL particle composition or oxidation state examined.
HDL is a complex macromolecular assembly of heterogeneous particles. Similar to low-density lipoprotein, it is prone to modifications, such as oxidation. We have previously shown that HDL and ApoA-I are selective targets of myeloperoxidase-mediated oxidation, and increased levels of myeloperoxidase-modified ApoA-I have been found in the circulation and atherosclerotic plaques of subjects with cardiovascular disease. [20] [21] [22] Furthermore, we have previously shown in vitro that myeloperoxidase-modified HDL or ApoA-I loses its ability to promote cholesterol efflux from macrophages-a crucial first step in RCT. 21 In the present study, we tested the effect of human native ApoA-I and oxidized (myeloperoxidase-modified) ApoA-I on RCT and atherosclerosis in mice. The degree of oxidation of ApoA-I in all our experiments was comparable to the degree found in ApoA-I isolated from human plaques based on protein-bound 3-chlorotyrosine levels. 22 After initial injection, circulating levels of native ApoA-I or oxidized ApoA-I at early time points (within 8 hours) were similar ( Figure I in the online-only Data Supplement). Although the injected native ApoA-I was almost completely associated with HDL particles in the plasma, the highly cross-linked oxidized ApoA-I was primarily found in the lipoprotein-deficient (≈65%) versus the HDL fraction (≈35%), similar to the state of ApoA-I recovered from human aortas. 24 Perhaps not surprisingly, then, only the native ApoA-I led to a significant increase of HDL-C levels and of RCT in ApoA-I-deficient mice, whereas this effect was impaired by myeloperoxidasecatalyzed oxidation of ApoA-I.
In addition to its intrinsic deficiency in promoting cholesterol efflux, a negative effect of oxidized ApoA-I on RCT may be indirect, for example, by competing with native ApoA-I. As noted in Results and Figure II in the online-only Data Supplement, experiments in vitro failed to disclose such a competition. Nonetheless, definitive evidence that these results reflect what occurs in vivo would require the administration of various ratios of native and oxidized ApoA-I to determine how much of the latter is needed to significantly impair the function of the former.
Assuming that a major atheroprotective effect of ApoA-I is based on its involvement in RCT, we went on to test whether oxidized ApoA-I injection was able to mediate changes in the composition and cellular phenotype of atherosclerotic plaques. In the face of severe hyperlipidemia in ApoE −/− mice, we did not observe significant changes in the plaque composition (reduced macrophage and lipid content, increased collagen content) within the short-term treatment with oxidized ApoA-I, whereas treatment with native ApoA-I was successful in this regard. In the present study, the analysis of atherosclerosis was performed only in aortic root plaques, the most commonly examined site in mouse studies. Whether the same results would be found throughout the arterial tree is an open question. 31 However, we have previously reported similar beneficial effects of ApoA-I on the plaque composition in aortic arches using a model in which an atherosclerotic aortic arch from an ApoE −/− donor mouse is transplanted into a hyperlipidemic ApoE −/− recipient mouse transgenic for human ApoA-I (ie, a mouse in which the naturally low HDL-C levels of the ApoE −/− mouse are restored to wild-type levels). 9 The homeostasis of plaque macrophages is regulated by the recruitment of circulating monocytes, their fate (apoptosis or secondary necrosis) within the plaque, their emigration from the plaques, and their local proliferation. 32 In an aortic transplant model (including the aforementioned one in which ApoA-I and HDL-C levels were raised in ApoE −/− mice) and other models of plaque regression, we have previously shown that macrophage emigration was associated with the upregulation of the chemokine receptor CCR7. 9, 25, 33 Similarly, we found in the present study that after the injection of native ApoA-I, the reduction of plaque macrophage (CD68 + ) cells was accompanied by a significant increase in their CCR7 expression, whereas this induction was dampened in the oxidized ApoA-I group in vivo and in vitro. The human and mouse CCR7 promoter contains sterol response elements, and thus, the cellular sterol content represents an important regulator of CCR7 gene expression. 26 In vivo, the reduction of cellular sterol content is indicated by the decrease in plaque cholesteryl ester content (as judged by Oil Red O staining), which was significant solely in the native ApoA-I treatment group and was consistent with a significant increase in the expression of another sterol-regulated gene, HMG-CoA reductase, in the plaque macrophages. We note, however, that the macrophages remaining in the native ApoA-I group still contained significant lipids, which might explain their persistence, and we speculate that additional treatment would have eventually cleared these cells from the plaques. In any case, the present study is the first report on CCR7 induction in plaque macrophages after the injection of exogenous ApoA-I, which also further emphasizes that this induction occurs in multiple models of atherosclerosis regression.
In our previous studies, we have also shown that during regression of atherosclerosis, the remaining macrophages in the plaques resemble more the anti-inflammatory M2 state. 9, [33] [34] [35] In the present study, the injection of native ApoA-I led to a decrease in the expression of inflammatory M1 markers (IL-1β, MCP-I) and an increase in the expression of anti-inflammatory M2 markers (arginase-I, mannose receptor 1); these effects were attenuated by the oxidation of ApoA-I. MCP-I is a potent recruitment factor of monocytes to atherosclerotic plaques and is expressed in macrophages and endothelial cells in response to inflammatory cytokines, such as IL-1. Consistent with our in vivo data, ApoA-I has previously been shown to inhibit IL-1β mRNA and protein expression of monocytes in vitro, 36 and a reduction of circulating MCP-I has been described in ApoE −/− mice after injection of ApoA-I. 37 Furthermore, Kirii et al 38 have reported that the knockout of IL-1β in ApoE −/− mice attenuates atherosclerotic lesion progression, which is accompanied by a decrease of MCP-I expression in the aortas of these mice. Taken together, our data suggest that even short-term treatment with native ApoA-I may reduce plaque inflammation through effects on multiple chemokine and cytokine-mediated pathways.
Despite the reduction in plaque lipid and macrophage content, we did not observe a significant reduction in plaque size in the native ApoA-I-injected mice within the short-term treatment period. The loss of plaque area from fewer macrophages could be compensated by an increase in extracellular matrix, as indicated by an increase in plaque collagen content (a marker associated with increased plaque stability in humans). In turn, the increase of collagen content in ApoA-I-injected mice likely resulted from increased synthesis, as indicated by an increased transforming growth factor-β and arginase-I expression (which is thought to promote collagen synthesis by M2 macrophages) in plaque CD68
+ cells, and a concomitant reduction of extracellular matrix degradation, as indicated by the trend of decreased matrix metalloproteinases activity ( Figure IV in the online-only Data Supplement). Based on our findings, it is tempting to speculate that the injection of native ApoA-I during the acute phase of a coronary event might efficiently and rapidly dampen inflammatory processes and promote plaque stability.
The underlying mechanism of the differential effects of native and oxidized ApoA-I is presumably based in part on the impairment of oxidized ApoA-I to promote ATP-binding cassette transporter A1-dependent cholesterol efflux in vitro and to reduce Oil Red O staining in vivo, as well as on the proinflammatory activity reported for myeloperoxidase-modified HDL. 22 Anti-inflammatory effects of ApoA-I on macrophages have been attributed to the interaction between ApoA-I and the ATP-binding cassette transporters, 39 thus providing a link between the impaired cholesterol efflux activity of oxidized ApoA-I and its lack of suppression of inflammation. There could also be differential effects of the ApoA-I forms on different underlying signal cascades, including the activation of the Janus kinase 2/signal transducer and activator of transcription 3 pathway, 40 the signal transducer and activator of transcription 6 pathway (required for polarization to the M2 macrophage state), 41 or the reduction of Toll-like receptor signaling, for example, via myeloid differentiation factor 88 and-nuclear factor κB, 42, 43 all pathways suggested to mediate anti-inflammatory effects in macrophages.
Also, as a likely result of its impaired ATP-binding cassette transporter A1-mediated cholesterol acceptor activity, oxidized ApoA-I was cleared more rapidly from the plasma compared with the native form, presumably because it remained lipid poor (as suggested by its high abundance in the lipoprotein-deficient fraction of the plasma). Although it cannot be excluded that this also had an impact on the attenuated effects of oxidized ApoA-I on many parameters, including a reduction in the level of endogenous ApoA-I as a result of the more rapid clearance of the oxidized protein, at the time of tissue harvesting, ApoA-I of either form (native or oxidized) was equally and abundantly detected in the aortic root plaques of the mice ( Figure III in the online-only Data Supplement).
It is interesting to consider our results in the context of the small clinical studies that have shown promising results on atherosclerosis by the infusion of reconstituted HDL or lipidpoor ApoA-I. [12] [13] [14] [15] Regression of coronary atheroma volume as assessed by intravascular ultrasound was found after the infusion of the Milano variant of ApoA-I and a reconstituted HDL (containing wild-type ApoA-I) in patients with acute coronary syndrome. 13, 15 In patients with peripheral artery disease undergoing femoral atherectomy, a single infusion of HDL led to a significant reduction in lipid content and markers of macrophage inflammatory activity, as shown by a lower percentage of cells expressing vascular cell adhesion molecule-1 and a smaller macrophage cell size (attributable to the diminished lipid content) in the excised plaque samples. 12 However, it still remains to be shown to which degree the observed beneficial effects on atherosclerosis translate into changes of cardiovascular outcome. More conclusive answers on this can be expected from ongoing larger clinical ApoA-I infusion studies and other HDL-raising approaches, such as by induction of endogenous ApoA-I 44 or by infusion of autologous delipidated HDL particles. 45 In conclusion, we have shown that injection of native (functional) ApoA-I into mice associates with plasma HDL particles, increases HDL-C levels, promotes RCT, and exerts beneficial effects on the plaque composition and the inflammatory state of plaque macrophages within a short-term treatment period. Our data complement the results from previous ApoA-I injection studies [3] [4] [5] 8, [11] [12] [13] 15, 46 and support the use of functional ApoA-I as a potential therapeutic to stabilize vulnerable plaques. In patients with high levels of myeloperoxidase activity, already established as a risk factor for coronary artery disease, 47, 48 these benefits may be lost by modifications to ApoA-I that render it dysfunctional. Thus, our results not only emphasize the importance of the functionality of HDL to reduce cardiovascular risk, but also suggest that the prevention of oxidation of ApoA-I by myeloperoxidase remains an interesting and potential therapeutic target for cardiovascular disease.
